Who from Vertex Pharmaceuticals is participating in the Guggenheim Inaugural Healthcare Innovation Conference, and when is it scheduled?

Vertex Pharmaceuticals will have Dr. Reshma Kewalramani participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 9:00 a.m. ET.

Who will represent Vertex Pharmaceuticals at the Stifel Healthcare Conference, and what is the date and time of this event?

Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at the Stifel Healthcare Conference on November 19, 2024, at 8:00 a.m. ET.

Where can investors access the live webcast of Vertex Pharmaceuticals' management during the investor conferences?

Live webcasts of the management's remarks will be accessible through the Vertex website, and a replay will be archived there as well.

What therapeutic areas does Vertex Pharmaceuticals specialize in, and what are some of their approved medicines?

Vertex Pharmaceuticals focuses on transformative medicines for serious diseases and has developed approved treatments for cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia.

When was Vertex Pharmaceuticals founded and where is its headquarters located?

Founded in 1989, Vertex has its global headquarters in Boston and has been recognized as one of the industry's top workplaces for 15 consecutive years.

Vertex to Participate in Upcoming November Investor Conferences

10/29/24 4:05:00 PM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRTX alert in real time by email

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences.

Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET.
Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241029053925/en/

Get the next $VRTX alert in real time by email

Recent Analyst Ratings for

$VRTX

Date	Price Target	Rating	Analyst
11/14/2024	$575.00	Buy	Citigroup
10/16/2024		Sector Perform	Scotiabank
10/10/2024		Mkt Perform	Raymond James
8/5/2024	$472.00 → $509.00	Overweight → Equal Weight	Barclays
6/27/2024	$545.00	Buy	Redburn Atlantic
4/11/2024	$438.00	In-line → Outperform	Evercore ISI
2/15/2024	$515.00	Outperform	Wolfe Research
2/6/2024	$436.00 → $438.00	Outperform → In-line	Evercore ISI

More analyst ratings

Vertex to Participate in Upcoming November Investor Conferences

Chat with this insight

Q&A

Who from Vertex Pharmaceuticals is participating in the Guggenheim Inaugural Healthcare Innovation Conference, and when is it scheduled?

Who will represent Vertex Pharmaceuticals at the Stifel Healthcare Conference, and what is the date and time of this event?

Where can investors access the live webcast of Vertex Pharmaceuticals' management during the investor conferences?

What therapeutic areas does Vertex Pharmaceuticals specialize in, and what are some of their approved medicines?

When was Vertex Pharmaceuticals founded and where is its headquarters located?

Recent Analyst Ratings for $VRTX

$VRTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

$VRTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Scientific Officer Altshuler David sold $7,178 worth of shares (15 units at $478.56), decreasing direct ownership by 0.06% to 25,813 units (SEC Form 4)

EVP & Chief Financial Officer Wagner Charles F Jr sold $1,554,810 worth of shares (3,000 units at $518.27), decreasing direct ownership by 6% to 44,137 units (SEC Form 4)

CEO & President Kewalramani Reshma sold $7,826,970 worth of shares (15,198 units at $515.00), decreasing direct ownership by 17% to 75,772 units (SEC Form 4)

$VRTX Press Releases

Fastest customizable press release news feed in the world

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Participate in Upcoming November Investor Conferences

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

$VRTX Leadership Updates

Live Leadership Updates

Vertex Appoints Nancy Thornberry to its Board of Directors

Vertex Appoints Michel Lagarde to its Board of Directors

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

$VRTX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$VRTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$VRTX Market Insights

Live Market Insights

$VRTX Financials

Live finance-specific insights

$VRTX SEC Filings

December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

Citigroup initiated coverage on Vertex Pharma with a new price target

Scotiabank initiated coverage on Vertex Pharma

Raymond James resumed coverage on Vertex Pharma

TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500

Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex Reports Second Quarter 2024 Financial Results

SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

Recent Analyst Ratings for
$VRTX

$VRTX
Large Ownership Changes

$VRTX
Insider Trading

$VRTX
Press Releases

$VRTX
Leadership Updates

$VRTX
FDA approvals

$VRTX
Analyst Ratings

$VRTX
Market Insights

$VRTX
Financials

$VRTX
SEC Filings